Astellas Pharma (OTCMKTS:ALPMY) Upgraded by Jefferies Financial Group to “Strong-Buy” Rating

Jefferies Financial Group upgraded shares of Astellas Pharma (OTCMKTS:ALPMY) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

Several other research analysts have also recently issued reports on the company. Citigroup cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Astellas Pharma currently has an average rating of “Hold”.

Astellas Pharma Stock Performance

OTCMKTS ALPMY opened at $15.99 on Tuesday. The stock has a market capitalization of $28.94 billion, a price-to-earnings ratio of 13.44 and a beta of 0.15. The business’s 50 day moving average is $15.21 and its two-hundred day moving average is $13.15. Astellas Pharma has a 12-month low of $8.37 and a 12-month high of $16.95. The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.29 by $0.15. Astellas Pharma had a return on equity of 23.62% and a net margin of 15.63%.The business had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.21 billion. Research analysts expect that Astellas Pharma will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).